RyanAleongMD

Cardiology • Aurora, CO

Cardiac Electrophysiology

Associate Professor, Medicine, University of Colorado School of Medicine

Join to view full profile

Dr. Aleong is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Aleong's full profile

Already have an account?

Office
12604 East 16th Avenue
Aurora, CO 80045
Phone+1 720-848-6510

Summary

Dr. Ryan Aleong is a cardiac electrophysiologist who works at the University of Colorado Hospital. He received his medical degree from University of Pittsburgh School of Medicine and has been in practice for 15 years. He is familiar with many cardiac ablation technologies, cardiac electronic implantable devices and lead extraction and has seen all of these technologies evolve.

He has also worked with the pharmacogenetics and has published extensively in this area.

Education & Training

Massachusetts General HospitalFellowship, Clinical Cardiac Electrophysiology, 2006 - 2007
UPMC Medical EducationFellowship, Cardiovascular Disease, 2003 - 2006
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1999 - 2002
University of Pittsburgh School of MedicineClass of 1999

Certifications & Licensure

CA State Medical License 2024 - 2026
CO State Medical License 2009 - 2025
WY State Medical License 2024 - 2025
KS State Medical License 2012 - 2019
MA State Medical License 2006 - 2010
PA State Medical License 2002 - 2010
American Board of Internal Medicine Cardiovascular Disease
American Board of Internal Medicine Clinical Cardiac Electrophysiology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial Start of enrollment: 2009 Nov 13
Completed
Not Applicable
Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation Start of enrollment: 2018 Oct 22
Completed
Phase 3
Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure Start of enrollment: 2014 Apr 01
Completed
Phase 2

Publications & Presentations

PubMed

304 citations
Mutation in glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) decreases cardiac Na+ current and causes inherited arrhythmias
Barry London, Michael Michalec, Haider Mehdi, Xiaodong Zhu, Laurie J. Kerchner
Circulation. 2007-11-13
1 citations
A polygenic risk score for the QT interval is an independent predictor of drug-induced QT prolongation.
Steven T Simon, Meng Lin, Katy E Trinkley, Ryan Aleong, Nicholas Rafaels
Plos One. 2024-01-01
66 citations
Ambulatory Rhythm Monitoring to Detect Late High-Grade Atrioventricular Block Following Transcatheter Aortic Valve Replacement
Karen Ream, Amneet Sandhu, Javier A. Valle, Rachel Weber, Alexander M. Kaizer
Journal of the American College of Cardiology. 2019-05-28

Journal Articles

Heart Block After Discharge in Patients Undergoing TAVR With Latest-Generation Valves
Sandhu A, Tzou W, Ream K, Valle J, Tompkins C, Nguyen DT, Sauer WH, Carroll JD, Messenger J, Aleong RG, J Am Coll Cardiol., 2/6/2018

Authored Content

Heart Block After Discharge in Patients Undergoing TAVR with Latest-Generation ValvesJanuary 2018

Professional Memberships

American College of Cardiology - ACC
Member